Oncology · Medical Literature
[Editorial] Drugging the undruggable in pancreatic cancer
Abstract
A new drug for pancreatic cancer set ASCO abuzz this May, uniting the plenary hall in standing ovation—in a phase 3 trial, the RAS inhibitor daraxonrasib nearly doubled overall survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Pancreatic cancer is a lethal disease, ranking 12th in global cancer incidence but sixth in cumulative mortality, with most patients not surviving beyond 1 year. Despite advances elsewhere in precision cancer treatments, KRAS, the key driver oncogene in PDAC, was thought to be undruggable.
Clinical relevance
In patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC), does the oral RAS(ON) multi-selective inhibitor daraxonrasib improve overall survival and progression-free survival compared with investigator's choice of cytotoxic chemotherapy? __SNAPSHOT__ {"studyDesign":"Phase 3, international, open-label, randomized controlled trial (RASolute 302; NCT06625320) — reported in an editorial context via The Lancet Gastroenterology & Hepatology; primary data simultaneously published in The New England Journal of Medicine","setting":"Global, multicenter; sites across North America, Europe, and Asia","sampleSize":"n=500 (daraxonrasib: n=248; chemotherapy: n=252)","population":"Adults with previously treated mPDAC who had received one prior fluoropyrimidine- or gemcitabine-based regimen for metastatic disease; ECOG Performance Status 0–1; median age 66; approximately 50% male; 91.8% with RAS G12 mutations","intervention":"Daraxonrasib 300 mg orally once daily — an oral, RAS(ON) multi-selective, non-covalent tri-complex inhibitor of the active GTP-bound state of mutant and wild-type RAS","comparator":"Investigator's choice of one of four standard-of-care cytotoxic chemotherapy regimens","primaryOutcome":"Dual primary endpoints: overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) in the RAS G12 mutant subpopulation","followUp":"Median follow-up 8.5 months (range 3.2–15.9 months); data cutoff February 10, 2026","fundingSource":"Industry — Revolution Medicines, Inc. (Nasdaq: RVMD)"}
Key findings
All primary and key secondary endpoints were met. In the RAS G12 mutant population (n=459 across both arms): median OS was 13.2 months with daraxonrasib vs. 6.6 months with chemotherapy; median PFS was 7.3 months vs. 3.5 months, respectively. In the overall population: median OS was 13.2 months vs. 6.7 months; median PFS was 7.2 months vs. 3.6 months. The hazard ratio for death in the overall population was reported as 0.40, representing a 60% reduction in risk of death (calculated absolute OS gain: 6.5 months; calculated absolute PFS gain: 3.6 months). Specific p-values and confidence intervals were not reported in the available abstract or press release sources. Objective response rate (ORR) in the RAS G12 population: 33.2% (daraxonrasib) vs. 11.8% (chemotherapy); in the overall population: 31.6% vs. 11.2%. Six-month PFS rates were 56.0% vs. 32.9% (calculated from reported figures). Survival benefit was consistent across RAS G12, G13, Q61 mutations, and RAS wild-type subgroups. Regarding safety: grade ≥3 adverse events occurred in 43.6% of daraxonrasib-treated patients vs. 57.5% of chemotherapy-treated patients. Treatment discontinuation due to adverse events was substantially lower with daraxonrasib (1.2% vs. 11.2%). The most common adverse events leading to dose reduction with daraxonrasib were rash and stomatitis; for chemotherapy, myelosuppression, thrombocytopenia, fatigue, diarrhea, and peripheral neuropathy predominated. Patient-reported quality-of-life outcomes significantly favored daraxonrasib, with delayed deterioration in cancer-related pain and global health status.
Practice implications
This is the first phase 3 RAS-targeted trial to demonstrate a large, statistically significant, and apparently clinically meaningful survival benefit in mPDAC — a disease where second-line chemotherapy has historically yielded median OS of only 6–7 months and median PFS of 3–4 months. The near-doubling of median OS (HR 0.40) alongside improved ORR, PFS, tolerability, and patient-reported quality of life represents a convergence of outcomes rarely seen simultaneously in pancreatic cancer trials. Crucially, daraxonrasib's activity against wild-type and multiple mutant RAS isoforms broadens potential eligibility beyond KRAS G12-specific cohorts. The drug has received FDA Breakthrough Therapy Designation and an expanded access program was initiated in May 2026 pending formal approval. IMPORTANT LIMITATIONS of interpretation: (1) Only abstract-level and press release data were available at time of this summary — full confidence intervals, p-values, subgroup interaction tests, and maturity of OS curves cannot be fully evaluated; (2) Median follow-up of only 8.5 months is short for an OS endpoint and tail behavior of survival curves is unknown; (3) The trial is open-label, precluding blinding of patients and investigators; (4) Industry sponsorship (Revolution Medicines) introduces potential for reporting and design bias; (5) The enrolled population was restricted to ECOG PS 0–1, limiting generalizability to patients with poorer performance status, who represent a substantial proportion of real-world mPDAC patients; (6) Long-term resistance mechanisms are not yet characterized. The results strongly support daraxonrasib as a new second-line standard of care for mPDAC, pending regulatory approval, but clinicians should await full peer-reviewed data and regulatory decisions before routinely adopting this therapy outside of expanded access programs. __LIMITATIONS__ 1. Open-label design introduces performance and detection bias in patient-reported and investigator-assessed outcomes. 2. Median follow-up of only 8.5 months is immature for an OS endpoint; long-term survival, cure fraction, and resistance patterns remain undefined. 3. Restricted to ECOG PS 0–1, excluding patients with poorer performance status — a common real-world mPDAC population. 4. Exclusively industry-funded (Revolution Medicines), with associated risk of publication, design, and reporting bias. 5. Full confidence intervals, subgroup interaction p-values, and hazard ratios for PFS were not available in the sources assessed for this summary. 6. Daraxonrasib is not yet regulatory-approved; expanded access is available but formal prescribing is premature. 7. Prior lines of therapy were limited to one; generalizability to more heavily pre-treated patients is unknown. 8. Resistance mechanisms to daraxonrasib are under investigation but not yet clinically characterized, limiting guidance on sequencing or combination strategies. 9. Comparative efficacy against emerging first-line regimens (e.g., daraxonrasib in 1L settings, currently under evaluation) cannot be assessed from this trial alone. __BOTTOM_LINE_CATEGORY__ practice_changing __BOTTOM_LINE__ The phase 3 RASolute 302 trial demonstrated that daraxonrasib — an oral, multi-selective RAS(ON) inhibitor — nearly doubled median overall survival (13.2 vs. 6.7 months; HR 0.40) and progression-free survival (7.2 vs. 3.6 months) versus chemotherapy in previously treated mPDAC, with a more favorable safety profile and improved patient-reported quality of life. These results, consistent across RAS mutation subtypes and wild-type disease, represent a landmark shift in the treatment of a historically recalcitrant malignancy. Regulatory approval is pending; clinicians should refer eligible patients to expanded access programs or ongoing trials while awaiting the full regulatory decision and mature long-term data.